Compare ResMed Inc. (RMD) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Western Union Co — how do they compare? ResMed Inc. trades at $225.92 (market cap $31.89B), while Western Union Co trades at $6.33 (market cap $1.97B). The key difference: ResMed Inc. is far larger — about 16.2× Western Union Co's market cap, and Western Union Co pays the higher dividend (14.85%). Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Western Union Co for 95 Days on average.
| RMD | WU | |
|---|---|---|
Market Cap | $31.89B | $1.97B |
Volume | 618,314 | 10,235,212 |
Sector | Health | Financials |
52-Week High | $277.88 | $10.28 |
52-Week Low | $182.82 | $5.90 |
Typical Hold Time | 51 Days | 95 Days |
Enterprise Value | $31.24B | $1.88B |
Dividend Yield | 1.16% | 14.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
Western Union (WU) trades at $6.11, down 0.49% on the day, with the stock showing bearish technical signals and mixed fundamental performance. Recent earnings show two misses in the last three quarters, though the company maintains strong profitability metrics including a 43.97% ROE and 9.79% net margin. The $200 million Beyond Efficiency Plan aims to revive profitability by 2027, while the pending Intermex acquisition faces regulatory hurdles in California.
WU presents a value opportunity with low P/E (5.1) and P/S (0.5) ratios, but faces execution risks from margin pressures and acquisition integration. Analyst consensus is cautious with a $6.86 price target, representing 12% upside, though recent technical weakness and earnings volatility warrant careful monitoring of the turnaround plan's progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
